SEROQUEL XLÂ (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest

The vent facts from the SEROQUEL XL® key depressive mix wakeful (MDD)1,2 and generalised anxiety disorder (GAD)3 clinical advance schema be presented at the 7th International Forum on apex of Mood and Anxiety Disorders (IFMAD) contained by means of Budapest. The data show that patients who received quetiapine XL hardened chief reduction in symptom strictness compare to those on placebo, in all of three tribunal, which investigate quetiapine XL by means of monotherapy in MDD1, adjunctive psychiatric assistance in MDD2 and as monotherapy in GAD3. The data be the first to be released from the AstraZeneca MDD/GAD clinical trial programme, which involve ended 7000 patients. Seroquel XL is not full up stop on in a minute licensed in the UK and do not currently individual license in encouragement of MDD or GAD.

GSK on Tuesday published intervening circumstance data from a company study on the NEJM Web site. The data represent no increased risk for cardiovascular events associated with Avandia (Saul/Harris, New York Times, 6/6). Warning Details The request from FDA for a black box warning for the labels of Avandia and Actos involved just increased risk for heart failure associated with the medications, not increased risk for heart attack (Alonso-Zaldivar, Los Angeles Times, 6/7). Von Eschenbach said that "these drugs be self prescribed to patients with significant heart failure," in offensiveness of customary warning on the labels of the cure (Rubin, USA Today, 6/7).

Dr Stuart Montgomery, Imperial College School of Medicine, University of London and head investigator in the MDD study said: "Seroquel have now demonstrated efficacy in unipolar collapse and generalised anxiety disorder. All of the dose of Seroquel XL examine in the studies provide improvement in MDD and GAD symptom and, importantly, Seroquel XL work in the blink of an eye, doing very well symptoms for patients within going on for a week of starting treatment." The second study (Phase III), also in patients with MDD examined quetiapine XL as extra to antidepressants2. After 6 weeks of treatment, MADRS scores were inherently reduced for both the 150mg/day dose (-15.26; P<0.01) and the 300mg/day dose (-14.94; P<0.01) versus placebo (-12.21). Onset of goings-on was swift, with significant unlikeness from placebo alleged from Week 1 (P<0.001).

Did you know? Best order duloxetine : quality, fast delivery, and super service on Qpills.net